Pamela Salman

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański et al. · New England Journal of Medicine · 2018 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · The Lancet Oncology · 2021 · 1.4K citations

Medicine, Oncology, Pharmacology +14

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Nicoletta Colombo, Coraline Dubot, Domenica Lorusso et al. · New England Journal of Medicine · 2021 · 992 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

Bradley J. Monk, Nicoletta Colombo, Krishnansu S. Tewari et al. · Journal of Clinical Oncology · 2023 · 236 citations

Medicine, Oncology, Pharmacotherapy +16

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial

Amir Sonnenblick, Dominique Agbor‐Tarh, Ian Bradbury et al. · Journal of Clinical Oncology · 2017 · 167 citations

Medicine, Oncology, Pharmacotherapy +17